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Abstract 
 
Estimates of healthcare costs for incident bronchiectasis patients are currently not available 
for any European country. Out of a sample of 4,859,013 persons covered by German 
statutory health insurance companies, 231 new bronchiectasis patients were identified in 
2012. They were matched with 685 control patients by age, gender and Charlson 
Comorbidity Index and followed for 3 years.  
The total direct expenditure during that period per insured bronchiectasis patient was 
€18,634.57 [95%CI: €15,891.02–€23,871.12], nearly one third higher (ratio of mean 1.31 
[95%CI: 1.02–1.68]) than for a matched control (P<.001).  
Hospitalization costs contributed to 35% of the total and were more than 50% higher in the 
bronchiectasis group (1.56 [95%CI: 1.20–3.01]; P<.001); on average, bronchiectasis 
patients spent 4.9 more days [95%CI: 2.27–7.43] in hospital (P<.001). Antibiotics 
expenditures per bronchiectasis outpatient (€413.81) were nearly five times higher than 
those for a matched control (4.85 [95%CI 2.72–8.64]). 
Each bronchiectasis patient had on average 40.5 [95%CI: 17.1–43.5] sick leave days and 
induced work-loss costs of €4,230.49 [95%CI: €2,849.58–€5,611.20]. 
The mortality rate for bronchiectasis and matched non-bronchiectasis patients was 26.4% 
and 10.5%, respectively (P<.001).  
Although bronchiectasis is considered underdiagnosed, the mortality and associated 
financial burden in Germany are substantial. 
 
Keywords: burden of illness; costs; cost analysis; bronchiectasis; mortality  
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Introduction 
 
Bronchiectasis is characterized by irreversibly dilated airways leading to chronic bacterial 
infection which leads to persistent productive cough, hemoptysis, shortness of breath and 
chronic fatigue. Patients also experience episodes of exacerbations [1]. Importantly, 
chronically infected patients, especially those infected with Pseudomonoas aeruginosa, 
may have reduced quality of life, require more frequent hospitalizations and carry 
significantly higher risk of death [2]. 
Pulmonary diseases other than cystic fibrosis (CF) may predispose patients to 
bronchiectasis, which is then referred to as non-cystic fibrosis bronchiectasis [3]. Whilst in 
up to 32-50% of bronchiectasis cases, no underlying conditions can be identified [3,4], 
recognized causes include lung infection by nontuberculous mycobacteria [5], connective 
tissue diseases [6,7], and allergic bronchopulmonary aspergillosis (ABPA) [8]. Many 
patients with bronchiectasis will initially be diagnosed with chronic airflow limitation [9] and 
thus may be misdiagnosed as chronic obstructive lung disease (COPD). On the other hand, 
bronchiectasis may be a secondary complication of asthma and COPD: As recently 
described by Quint et al. [10], 42.5% of bronchiectasis patients in the UK had a coexisting 
diagnosis of asthma and 36.1% had a coexisting diagnosis of COPD.  
Although bronchiectasis has previously been classified as an “orphan disease,” its 
incidence is now considered to be increasing worldwide [10,11]. As more patients require 
appropriate management, it is necessary to assess the resource requirements for treatment 
of bronchiectasis within the various European healthcare systems. However, estimates of 
healthcare costs for newly diagnosed bronchiectasis patients are currently not available for 
any European country. Therefore, the objective of the current study was to estimate the 
burden of illness associated with incident bronchiectasis in Germany.  
 
Methods 
 
Setting and Data Collection 
This study was a population-based cohort study with a nested case-control design, based 
on administrative data from statutory company health insurance (SHI) funds from all 
regions of Germany. The data were provided to us by the database service provider sgh 
consulting, Hamburg (www.sgh-consulting.de). The health claims database of that 
company comprises anonymized billing data from longitudinally linked records of 
4,850,013 insured persons (effective date: 31 July 2017) and is representative with 
respect to age and sex for the around 70 million Germans mandatorily insured under the 
SHI scheme. Patients with bronchiectasis were identified based on the 10th revision of 
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the International Classification of Diseases (ICD-10) GM (German modification) code J47. 
Patients classified as having newly diagnosed bronchiectasis were identified in the year 
2012 and tracked over 3 years after the first (index) quarter in which J47 was coded.  
Patients were classified as having incidental bronchiectasis if they met the following criteria: 
(a) at least one medical claim with a documented ICD-10 GM code J47 as an inpatient or 
with a verified diagnosis as an outpatient and (b) no documented ICD-10 GM code J47 in 
the eight quarters prior to the index quarter in 2012. (Figure 1). Patients with bronchiectasis 
who either had an ICD-10-GM diagnosis code E84.- (cystic fibrosis) or Q33.4 (congenital 
bronchiectasis) were excluded.  
                                 
For calculating the increase in healthcare costs attributable to the presence of 
bronchiectasis, control patients without bronchiectasis were randomly assigned an index 
quarter in 2012 according to the distribution of index quarters in bronchiectasis patients. 
These were followed for the period of a total of 3 years without limitation to a calendar year, 
or until death. The control group was matched to the group of bronchiectasis patients at a 
ratio of 3:1 in regard to age, gender and in terms of their distribution and level of 
comorbidities. Therefore, patients’ comorbidities were assessed and measured using the 
Charlson Comorbidity Index (CCI) score, a claims-based measure of overall disease burden 
based on the occurrence of at least one of 17 comorbidities identified using the ICD-10 GM 
coding manual [12, 13], and the frequency of comorbidity patterns of the matched non-
bronchiectasis sample were as closely related as possible to those of the bronchiectasis 
patients.  
As some diseases are known to be extraordinary cost drivers and therefore may bias the 
results of the study, bronchiectasis patients as well as control patients were excluded a 
priori if they suffered from one of the diseases that exceeded an amount of €20,000 in 
allocation according to the German morbidity-based risk structure equalization (“high-cost 
cases”)    [14]. 
Costs over the entire follow-up period were retrieved for five different categories: inpatient 
care (hospitalization), outpatient visits and diagnostics, prescribed pharmaceuticals 
according to German national drug (ATC) codes, remedies (physiotherapy treatments and 
modalities, such as active cycle of breathing and postural drainage techniques), medical 
aids (especially nebulizers and respiration therapy equipment) and sick pay. Furthermore, 
the top twenty prescribed drugs for bronchiectasis management were analyzed and 
compared to those of the non-bronchiectasis group. 
 
Calculation of Loss of Productivity due to bronchiectasis (Indirect Costs) 
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In accordance with the human capital approach, indirect costs refer to the productivity loss 
for the national economy caused by absence from the workplace on sick leave. 
According to the German Hanover Consensus [15] the per-day average productivity loss 
figure used to cover the self-employed income as well is calculated as: sick leave days × 
(gross income from non‒self-employed work for the respective year/ 365 days).  
The follow-up time period after diagnosis of a bronchiectasis patient amounts to a maximum 
of 36 months. As per-day employer cost for employee compensation in Germany increased 
slightly but continuously from 2012 (2012: €101.19; 2013: €103.28; 2014: €106.18; 2015: 
€108.74 [16]) our assessment considered the exact calendar year within which the 
observation period of an individual bronchiectasis patient or a matched control was on sick 
leave. We multiplied the amount of per-day employer costs of a given year between 2012 
and 2015 with the number of lost working days of the patients in the respective year to arrive 
at our total amounts.    
 
Statistical Analysis 
Frequency and percentages were reported for categorical variables. For descriptive 
analyses, mean, standard deviation (SD), 95% confidence interval (CI), and median were 
reported for all continuous variables. To compare bronchiectasis patients and matched 
controls, appropriate univariate tests (i.e., chi-squared test of independence for categorical 
variables and the Wilcoxon-Mann-Whitney test for continuous variables) were used. 
Differences were considered significant if the two-sided P-value was less than .05. Ratios 
of the mean (RoM), including 95% confidence intervals, were calculated for continuous 
outcomes.   
Mortality was determined separately between both groups yearly and at the end of the study 
period. We generated a Kaplan-Meier survival plot and used a log-rank test to prove 
whether the difference in survival times between the bronchiectasis and the non-
bronchiectasis group was statistically significant. Cox regression, adjusted to group 
membership (bronchiectasis or non-bronchiectasis), age, and presence of COPD as 
comorbidity, was employed to calculate the Hazard Ratio (HR) of all-cause mortality 
All costs are reported in Euros (€) in 2012 and the respective follow-up years in which they 
were incurred.  
 
 
Results 
 
Patient characteristics  
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After exclusion of four “high-cost” cases, two out of the bronchiectasis and two out of the 
control group, a total of 231 bronchiectasis cases and 685 matched controls met the study 
criteria and were included in the analysis. The mean age of bronchiectasis patients and of 
matched controls was 58.6 years [95%CI: 56.3–60.9], and 58.5 years [95% CI: 57.2–59.8), 
respectively. 61.5% of the patients were male and 39.5% were female. Patient´s mean CCI 
total score was equally high among both groups with 2.70 [95% CI: 2.4–3.0) in the 
bronchiectasis group and 2.76 (95% CI: 2.6–2.9) in the matched control group.  
With respect to the most frequently represented diseases out of the range of predefined 
comorbid conditions in the CCI, more bronchiectasis patients (128/231, or 55.4%) than 
matched controls had the diagnosis COPD (J44.-) (Table 1). Nevertheless, COPD was also 
the most frequent comorbid condition (246/685, or 35.9%) in the control group. There were 
no significant differences between the two groups in the frequency of asthma (J45.-; 28.1% 
of the bronchiectasis patients and 27.0% of the controls), and in the frequency of 
gastroesophageal reflux disease (K21.-; 14.7% of all cases in both groups). Coronary heart 
disease (I25.-) was observed in 15.6% and 15.3%, respectively, and heart failure (I50.-) in 
11.7 and 10.1%.  
 
Incidence of bronchiectasis 
The age- and gender-adjusted incidence rate for bronchiectasis in 2012 was 6.1 per 
100.000 insured German inhabitants [95%CI: 6.0–6.3] (Table 2), whereby males aged over 
65 years contributed mostly with an incidence of 21.68 [95%CI: 20.57– 22.86] per 100.000 
persons of that age group. 
 
Direct Costs 
For patients with bronchiectasis, the total direct expenditure over the follow-up period per 
insured patient was €18,634.57 [95%CI: €15,891.02–€23,871.12], which was nearly one 
third (RoM 1.31 [95%CI: 1.02–1.68] higher than the expenditure for a matched control 
(€14,236.99 [95% CI: €11,318.77–€17,155.21]); P<.001 (Table 3). 47.6% of the 
bronchiectasis patients were hospitalized at least once during follow-up, and more than one 
third, or 34.9%, of the total cost (€6504.37 [95%CI: €5,098.02–€7,909.82]) could be 
attributed to costs accrued in the hospital sector. Whilst the diagnostic and drug costs in the 
outpatient setting did not differ between bronchiectasis patients and matched controls, 
hospital costs were 56% higher in the bronchiectasis group (RoM 1.56 [95%CI: 1.20–3.01]; 
P<.001). It was striking that bronchiectasis patients were more often (62%) prescribed 
mucoactive therapies, and that the costs of those agents were nearly 5 times higher in 
bronchiectasis patients with €70.11 per bronchiectasis patient versus €14.15 per control 
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patient (RoM 4.96 [95%CI: 4.91–5.28]; P =.001). Also the costs of medical aids, especially 
inhalation and home ventilation devices, were nearly three times higher in bronchiectasis 
patients (RoM 2.75 [95%CI: 1.95–3.90]; P<.001) (Table 3). On average, bronchiectasis 
patients spent 4.85 more days [95%CI: 2.27–7.43] in hospital during the observation period 
(Table 4).  
 
The major part of the direct total costs, however, were drug costs in the outpatient setting 
accumulating to €7694.56 [95%CI: €5,354.77–€9,944.35], which accounted for 41.3% of 
total direct costs. On average, the frequency of visits per bronchiectasis patients to a chest 
physician was 83% higher (2.51 [95%CI: 2.34– 2.90] versus 1.37 [95%CI: 1.24 –1.50]; 
P<.001) and visits to a radiologists were also 28% higher (2.89 [95%CI: 2.57–3.03] versus 
2.26 [95%CI: 2.12–2.35; P<.001]) within the 3-year follow-up period (Table 4).   
 
Antibiotic Treatment  
Of the 231 patients with newly diagnosed bronchiectasis, 88.2% were prescribed any type 
of antibiotics in the outpatient setting during the entire 3-year follow-up period, but only 
59.7% patients of the matched control group (P<.001).  In total, costs of antibiotics for 
bronchiectasis outpatients amounted to €87,728 and €56,219 for the matched control 
patients. Out of a total 861 prescriptions, fluoroquinolones were the most prescribed 
antibiotics in bronchiectasis patients (326 prescriptions, or 37.9%) followed by 
aminopenicillin (187 prescriptions, or 21.7%) and macrolides (90 prescriptions, or 10.5%).  
Overall, only 8 bronchiectasis patients (0.35%) and none of the control patients received 
inhaled antibiotics (all colistin) during the observation period. Thirteen out of the 231 
patients (5.6%) received monotherapy with clarithromycin or azithromycin for at least two 
subsequent quarters, indicating that this therapy was administered for maintainance 
treatment of bronchiectasis rather than for treating other respiratory infections. Of note, 
parenteral antibiotics (eg, amikacin, ceftazidime or imipenem) were not prescribed for any 
bronchiectasis patient in the outpatient setting.  
 
Treatment with bronchodilators 
Costs of inhaled bronchodilators (ATC-R03) per bronchiectasis patient, of which salbutamol 
and long acting beta-2 agonists, such as salmeterol and formoterol, had particularly often 
been prescribed, were nearly 50% (RoM 1.49% [95%CI 1.37-1.52]) higher than in the 
matched controls (€1,595.42 [95%CI: €1,444.99–€2,048.6] versus €1,069.03 [95%CI: € 
917.46–€1,136.46). 82.1% of bronchiectasis patients, but only 56.3% of the matched 
controls claimed at least one ATC-R03 prescription during the 3-year follow-up period.  
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Treatment with other drugs 
As expected, costs of mucoactive drugs during the observation period were significantly 
higher (nearly 5 times) with €70.11 per bronchiectasis patient versus €14.15 per control 
patient (4.96 [95%CI: 4.95–4.98]; P<.001) and costs of topical nasal corticosteroids were 
nearly 4 times higher with €21.57 versus €6.06 (3.56 [95% 3.55–3.58]; P<.001].  
 
Ranking of drugs prescribed for bronchiectasis patients and matched controls 
As can be seen in Table 5, drug prescriptions in both groups focused on long-acting beta-
2 agonists (LABA), used with or without inhaled steroids, and the antibiotics amoxicillin, 
ciprofloxacin and cefuroxime axetil. Significant differences between bronchiectasis patients 
and their matched controls could only be found with respect to the use of azithromycin and 
aclidinium bromide, the latter being a long acting muscarinic agent which before 2012 had 
not been approved in the EU for treating COPD.  
 
Mortality  
Differences in all-cause mortality rates per year between the three groups of bronchiectasis 
patients with COPD, without COPD and matched controls are shown in Figure 2. Sixty-one 
of the initial 231 diagnosed patients in the bronchiectasis group (26.41%), but only 72 of the 
initial 651 patients in the control group (10.5%), died within the 3-year follow-up period 
(Table 6, P<.0001, log-rank test).  When using Cox´s regression and only adjusting for 
disease group, bronchiectasis patients had a nearly fourfold higher risk of death (HR: 3.64; 
95%CI: 2.28–5.77; P<.0001). When adjusting for age, gender and the presence of COPD 
as co-morbidity, gender and the presence of COPD had no significant influence on the 
hazard ratio, whilst bronchiectasis patients had a relative 5.8 % increase in mortality rate 
per life year compared to the matched controls. 
 
Cost due to Loss of Productivity  
bronchiectasis patients had on average 40.5 [95%CI: 17.1–43.5] sick leave days during the 
follow-up period and induced indirect costs of €4,230.49 [95%CI: €2,849.58–€5,611.20]. 
However, for the same period also in the matched controls 45.7 [95%CI: 39.5-51.9] sick 
leave days and a productivity loss of €4,776.50 [95%CI: €4,127.84–€5,425.15] were found. 
Cost due to absenteeism from work amounted to €1,916.43 per bronchiectasis patient in 
the first year of follow-up and decreased slightly to €1,273.61 by the third year. Considering 
that total direct medical costs of bronchiectasis patients amount to €18,634.57, work-loss 
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costs in bronchiectasis patients are 25.6% of that amount. The work absence burden for 
employees with bronchiectasis was not significantly different from that for matched controls.  
 
Discussion 
 
The objective of this study was to provide the first comprehensive estimate of the economic 
burden of incident bronchiectasis bronchiectasis in any European country. This was 
accomplished by a retrospective observational design comparing medical and productivity-
related expenditure for 231 bronchiectasis patients to a 1:3 matched comparison group of 
685 control patients without bronchiectasis over a period of three years in Germany. The 
economic burden attributed to bronchiectasis is expected to be great, because it is a chronic 
disease that may require frequent medical consultations, long-term treatment with 
multimodal regimens, and hospitalizations for pulmonary exacerbations in order to minimize 
the risk of further progression. However, to date, published annual cost data for treatment 
of bronchiectasis are sparse:  
The studies of Sanchez et al. [17] and de la Rosa et al. [18], which retrospectively 
determined the hospital costs of bronchiectasis in Spain (cost year 2013), reported mean 
costs of €4,672 ± €6,281 per patient [17] or €3,515 for patients with bronchiectasis as a 
primary diagnosis and €4,559 for patients with a secondary diagnosis [18]. Three North 
American studies calculated the annual costs of prevalent bronchiectasis patients ranging 
from US$13,244 (cost year 2001) [19] to over US$37,030 (in patients with exacerbation, 
2008–2011 [20]) and up to US$67,764 (in patients with Pseudomonas aeruginosa, 2007–
13 [21].  
With respect to incident bronchiectasis patients, only the study of Joish et al. [22] examined 
the increase in resource use and costs for patients with bronchiectasis before and after the 
first year of diagnosis. US MarketScan Research data were analyzed for the period from 
2005 to 2009 for patients diagnosed with bronchiectasis (n = 9,146) and controls without 
bronchiectasis (n = 27,438) who were matched to each bronchiectasis patient based on 
age, gender, geographic region and type of health plan enrolled in an 3:1 ratio. This resulted 
in an increase of US$2,319 per bronchiectasis patients in the 1st year after diagnosis, but 
of only US$1,607 for control patients. However, in contrast to our study, where COPD as 
one of the most important associated condition  of bronchiectasis was explicitly allowed in 
both bronchiectasis cases and control patients, individuals with COPD were excluded if the 
claim was either 12 months prior (baseline) or during the subsequent 12-month follow-up 
period.  
To our knowledge, our pilot study represents the first investigation of healthcare resource 
use and costs brought about by incident bronchiectasis cases worldwide who were matched 
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according to type and severity of their comorbidities and for which accumulated post-
diagnosis costs have been followed for several years. Furthermore, it includes – for the first 
time – both mortality and costs due to lost patient productivity.  
 
When considering only respiratory-related resource utilisation, bronchiectasis outpatients 
sought 80% more often specialized respiratory care, were 30% more often referred to 
radiologists (see Table 4). Based on records for the 25 most-prescribed drugs for both 
groups, we found no notable difference between the two groups in prescription patterns for 
antibiotics addressing exacerbations (fluoroquinolones, aminopenicillins and macrolides) 
nor for bronchodilators (predominantly salbutamol and LABAs) (see Table 5). In total, 
however, bronchiectasis patients received 27% and 29% more frequently prescriptions for 
bronchodilators and antibiotics, respectively, than was the case with controls (all P<.001).  
 
Beyond the expected economic burden on the healthcare system, mortality in our 
bronchiectasis group after 3 years of follow up was surprisingly high at 26.4%. Whilst in 
Cox´s regression the presence of COPD had no significant influence on mortality when 
comparing the bronchiectasis group and the whole matched control group in which also a 
considerable proportion of patients (35.9%) had COPD, mortality in the bronchiectasis 
group was nearly four times higher (HR 3.73; 95%CI: 2.52–5.53) than in the COPD-free 
part of the matched patient group. This is in line with recently published evidence [23] that 
mortality may be higher among those who also had COPD than in patients with 
bronchiectasis alone. Because mortality in the bronchiectasis group was highest at 8.23% 
[95%CI: 5.33–12.49] within the first year following diagnosis, immediate and appropriate 
medical treatment should be offered as complications may arise.  
 
Apart from the contribution of COPD, we were not able to investigate the reasons for the 
high mortality found among bronchiectasis patients. It may, however, be speculated that – 
regular chest x-ray being generally insensitive to the changes caused by bronchiectasis – 
high resolution computer tomography (HRCT), the radiological investigation of choice, was 
performed too late. Thus, a considerable fraction of bronchiectasis patients may have been 
chronically infected with bacterial pathogens well before the diagnosis of bronchiectasis 
was made. Unfortunately, we could not evaluate P. aeruginosa infection in our study sample 
as ICD-10 coding of bacterial pathogens is voluntary in Germany and therefore not routinely 
performed by physicians in the outpatient setting where more than 90% of bronchiectasis 
patients are cared for [9]. According to data from the representative German Bronchiectasis 
Registry PROGNOSIS (The PROspective German NOn-CF bronchiectaSIS patient 
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registry)  which is part of the European Bronchiectasis Initiative EMBARC [24] and which 
currently has recruited more than 1000 patients, P. aeruginosa  is the most prevalent 
pathogen during stable disease and during pulmonary exacerbations with detection rates 
of 30% and 36% respectively [25]. A high proportion of bronchiectasis patients [40.3% 
(93/231)] were hospitalized at least once in the first year following diagnosis. This 
observation suggests that the sicker patients whose disease was already fairly advanced 
at diagnosis may have started treatment with medication that proved at least partly 
ineffective with regard to the prevention of severe exacerbations requiring hospitalizations. 
This may have contributed to the poor prognosis of these patients within the follow-up 
period.  
 
We also took into account reduced productivity caused by ongoing symptoms and 
exacerbations of bronchiectasis, which amounted to €1,916.43 per bronchiectasis patient 
the first year of follow-up and decreased slightly to €1,273.61 in the third year. As the total 
cost of €4,230.39 per bronchiectasis patient due to absenteeism from work that occurred 
within the 3 years of observation accounted for 22.7% of the burden caused by direct total 
costs, indirect costs may be considered to have a substantial economic impact on 
healthcare. Because short-term disability with sick leave days of less than 3 days is not 
captured by the SHI, these costs are most certainly underestimated in our calculations. The 
importance of indirect costs in bronchiectasis patients is not diminished by the fact that 
these did not differ significantly from the indirect costs in the matched control group, which 
was characterized  not only by an equally high percentage of COPD (35.9%) but also by a 
comparable prevalence of cardiac comorbidities and asthma.   
 
When extrapolating our age- and gender adjusted incidence rate for bronchiectasis of 6.1 
per 100.000 insured German inhabitants (with a 95% confidence interval between 6.0 and 
6.3) and keeping this incidence rate constant, on average a total of 5045 (4962 at minimum 
and 5210 at maximum) newly diagnosed bronchiectasis patients per year can be expected 
in the 2017 German population of 82.7 million [26], whereby males aged over 65 years, 
probably due to a high rate of concomitant COPD, are the most strongly represented 
bronchiectasis subpopulation.The annual direct and indirect expenditures attributable to the 
disease can be expected to amount to more than €38.45 million per year (€37.82 million at 
minimum and €39.71 million at maximum). 
 
Our analysis was limited by several factors. First, we only followed bronchiectasis patients 
for 3 years after the quarter when the diagnosis was established and thus did not capture 
11
 
the long-term burden of the disease. Accordingly, future studies of the long-term costs of 
bronchiectasis that also take the burden arising from prevalent cases into account are 
warranted. Second, other costly comorbid conditions that were not accounted for via the 
CCI in the matching process may have influenced the cost burden estimates. Third, beyond 
determining the difference of costs with respect to the presence or non-presence of 
bronchiectasis, matching on the basis of an equivalent CCI score level does not allow to 
determine the costs of COPD or other diseases included in the CCI separately.  
Fourth, although the number of insured persons from which bronchiectasis patients and 
their controls were taken was large at more than 4.8 million, our patients were not formally 
selected as part of a representative sample. Furthermore, our higher proportion of males 
with bronchiectasis, a disease considered more common in women than in men in Western 
countries, [27,28] may reflect the generally higher proportion of insured males in all age 
groups of our study population, which in 2012 included in total 614,744 more males than 
females in German health insurance funds [29]. Thus, it is not certain whether our results 
may be generalized to the entire German population. In addition, patients were only 
included in our analysis if they had no diagnosis of bronchiectasis within the 3 years prior 
to the coding date in 2012, and if they were continuously eligible for comprehensive health 
benefits in the 3 years following the diagnosis. Consequently, the figure of 6.1 newly 
diagnosed bronchiectasis patients per 100.000 insured persons in our sample is lower than 
those estimated in the recently published studies of Quint et al. [10] and Weycker et al. [11] 
with 21.2 and 29 incident cases per 100.000 person-years in the UK and the U.S., 
respectively.  
 
Nevertheless, our results not only demonstrate that per patient spending on bronchiectasis 
is high but also suggest that efforts at providing earlier and more effective treatment are 
warranted with a view towards lowering both mortality and costs. Indeed, although the 
present findings have to be seen in the context of the German healthcare system, we expect 
that studies subsequently performed in other Western countries would arrive at similar 
economic conclusions. However, although European Guidelines have recently been 
published [26], they have not yet been implemented in Germany. However, national 
guidelines are desperately needed given the drastic risk of refund claims for costly off-label 
prescriptions from SHI companies, as indicated by the infrequent use of inhaled antibiotics 
in our “real life” study sample.  
 
Conclusions  
Although bronchiectasis is considered to be underdiagnosed, the mortality and the 
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associated financial burden in Germany are substantial. Efforts to manage bronchiectasis 
costs may be directed at reducing hospitalization expenditures, which are the main cost 
drivers. Providing early and effective therapeutic interventions that can prevent disease 
progression may further reduce the associated economic burden of bronchiectasis.  
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Figures  
 
Figure 1. Patient-individual observation periods  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
*Example of a quarter of the first bronchiectasis diagnosis in 2012. Only verified diagnoses are 
considered in the outpatient setting whereas all types of diagnoses (primary and secondary 
diagnoses) are considered in the inpatient setting. 
 
**All quarterly information refers to the patient-individual follow-up period relative to the index 
quarter.  
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Figure 2. Mortality rates among bronchiectasis patients, matched control (MC) patients and bronchiectasis patients without COPD within 36 
months of observation 
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 Tables 
 
Table 1. Most frequent diseases out of the range of CCI comorbid conditions in 
bronchiectasis and matched control patients* 
 
ICD-10-
GM 
Code 
Description bronchiectasis 
patients (no.) 
bronchiectasis 
patients (%) 
Matched 
controls 
(no.) 
Matched 
controls 
(%) 
P-
Value 
J44.- COPD 128 55.4 246 35.9 <.001 
J45.- Asthma 65 28.1 185 27.0 
ns  
(0.78) 
K21.- 
Gastro-
oesophageal 
reflux 
disease 
34 14.7 101 14.7 
ns  
(0.78) 
M06.- 
Other chronic 
polyarthritis 
6 2.6 17 2.5 
ns  
(1.0) 
I25.- 
Coronary 
Heart 
Disease 
36 15.6 105 15.3 
ns  
(0.77 ) 
I50.- Heart failure 27 11.7 69 10.1 
ns  
(0.77) 
 
*multiple entries are possible 
ns: not significant 
 
 
                           
 
Table 2. Age- and gender-adjusted incidence rate of bronchiectasis patients included in the 
study 
 
Age group (yr) Gender 
Patients 
(no.) 
per 100.000* 
Lower 95% 
CI  
Upper 95% CI 
< 15 female 0 0.00 000 0.00 
 15 to 65 female 863 3.66 3.42 3.91 
> 65 female 1,036 11.38 10.71 12.10 
total female 1,899 5.13 4.91 5.37 
< 15 male 124 2.74 2.28 3.27 
15 to 65  male 903 4.03 3.78 4.31 
> 65 male 1,390 21.68 20.57 22.86 
total male 2,417 7.25 6.97 7.55 
< 15 total 124 1.40 1.17 1.68 
15 to 65 total 1,766 3.84 3.66 4.03 
> 65 total 2,426 15.64 15.03 16.28 
total total 4,316 6.14 5.96 6.32 
 
18
 
*per 100,000 persons under risk. Incidence rate refers to a population of 4,850,013 insured 
members who could be followed for the entire period of 36 months.
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  Table 3. Total cost of bronchiectasis and costs separated by main cost types compared with matched controls after  
   adjusting for age, sex, and Charlson Comorbidity Index scores 
  
  
  
Control group without bronchiectasis 
(N=685) 
Incident bronchiectasis patients 
(N=231) 
Ratio of the 
mean (RoM) 
P-
Value** 
Sum (€) Mean (€)‡ 95% CI Sum (€) Mean (€)‡ 95% CI RoM 
95% 
CI 
Outpatient 
diagnostic and 
visiting costs* 
1,840,235.71 2,792.47 
2,699.33 -
2,885.61 
632,567.17 2,983.81 
2,795.81 -
3,171.81 
 
1.07 
 
0.995-
1.15 
ns (0.27)     
Costs of 
remediesƒ*** 
158.094,73 239.9 
215.44 -
264.36 
82,556.87 389.42 
301.68 -
477.16 
1.62 
1.27-
2.08 
0.02  
Medical aids 
costs‡*** 
259,848.97 394.31 
300.36 -
488.26 
230,186.30 1,085.78 
809.87 -
1,361.69 
2.75 
1.95-
3.90 
<.001 
Sick pay costs¥ 14,603.98 22.16 
16.33 -
27.19 
4,586.89 21.64 12.63-30.65 0.98 
0.60-
1.60 
ns (0.8)      
Hospitalization 
costs 
2,757,026.84 4,183.65 
3,577.8 -
4,789.5 
1,378,925.53 6,504.37 
5,098.02 -
7909.82 
1.56 
1.20-
3.01 
<.001 
Drug costsƃ*** 4,352,366.43 6,604.5 
3,757,13 -
9,451,87 
1,621,706.53 7,694.56 
53,54.77 -
9,944.35 
1.16 
0.69-
1.95 
ns (0.67) 
Costs of 
antiobstructive 
medication*** 
704,490.03 1,069.03 
917.46 -
1,136.46 
338,229.90 1,595.42 
1,444.88-
2,048.6 
1.49 
1.37 - 
1.52 
<.001 
Costs of 
antibiotics*** 
56,691.69 85.31 77.80-92.82 87,727.50 413.81 
176.28-
651.34 
4.85 
2.72-
8.64 
<.001 
Costs of 
mucoactive 
agents 
9322.73 14.15 10.51-16.79 14,863.81 70.11 51.65-88.57 4.96 
 
4.91-
5.28 
 
.001 
Total cost 9,382,176.66 14,236.99 
11,318.87 -
17,155.21 
3,950,529.29 18,634.57 
15,891.02 -
23,871.13 
1.31 
1.02-
1.68 
<.001 
             CI: Confidence interval; RoM: Ratio of the mean  
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 * Outpatient costs comprise reimbursement for outpatient physician´s office visits, laboratory diagnostics and imaging 
 ** Wilcoxon-Mann-Whitney (two-sided) 
 *** as outpatients  
ƒRemedies comprise physiotherapy treatments and modalities such as active cycle of breathing and postural drainage techniques 
† Medical aids comprise nebulizers and respiration therapy equipment 
¥ Sick pay is paid out in the SHI as a substitute wage from day 43 of the sick leave according to §44 of the 5th German Social Code (SGB V). 
ƃ Prescribed pharmaceuticals according to German national drug (ATC) codes 
 ‡ adjusted to patients who died during the observation period 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Disease-related event numbers for bronchiectasis patients compared with matched controls 
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Control group without 
bronchiectasis 
(N=685) 
Incident bronchiectasis 
patients  
(N=231) 
Ratio of the 
mean 
 P-Value** 
Sum Mean 95% CI Sum Mean 95% CI RoM 95% CI 
No. outpatient 
appointments  
15,427 23.41 22.8-24.02 5,230 24.67 23.32-26.01 1.05 
0.99-
1.12 
ns (0.12 ) 
No. outpatient 
appointments 
(general 
practitioner) 
5,479 9.83 9.6-10.02 631 9.18 8.77-9.59 0.93 
8.77-
9.59 
0.002 
No. outpatient 
appointments  
(chest 
physicians) 
901 1.37 1.22-1.52 901 2.51 2.24-2.78 1.83 
1.57-
2.14 
<.001 
No. outpatient 
appointments 
(cardiologists) 
488 0.74 0.66-0.82 172 0.81 0.55-0.95 1.10 
0.90-
1.33 
ns (0.60)     
No. outpatient 
appointments 
(radiologists) 
1,490 2.26 2.12-2.35 612 2.89 2.57.-3.03 1.28 
1.21-
1.43 
<.001 
No. sick leave 
days  
30,111 45.69 39.49-51.89 8,897 40.50 27.28-53.72 0.89 
0.62-
1.26 
ns  (0.18)      
No. hospital days 9,746 14.79 13.92-15.66 4,163 19.64 15.96-23.32 1.33 
1.09-
1.61 
<.001 
 
CI: Confidence interval; RoM: Ratio of the mean  
 
**Wilcoxon-Mann-Whitney (two-sided) 
 
‡ adjusted to patients who died during the observation period 
Table 5. Top 25 of prescribed drug for bronchiectasis patients compared to matched controls 
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ATC-
Code 
Agent Percentage of 
prescriptions for 
bronchiectasis 
patients 
Prescrip- 
tions 
(no.) 
Rank Prescriptions 
per 
bronchiectasis 
patient 
Percentage of 
prescriptions  for 
control patients 
Prescrip- 
tions 
(no.) 
Rank Prescriptions 
per control 
patient 
P-
Value* 
R03AC02 Salbutamol 30.66% 449 1 6.91 32.02% 1.396 1 6.62 
ns 
(0.75) 
R03AK07 Formoterol/Budesonide 22.64% 334 2 6.96 18.21% 849 4 7.08 
ns 
(0.96) 
J01CA04 Amoxicillin 21.23% 95 3 2.11 18.66% 266 3 2.16 
ns      
(0.82) 
J01MA02 Ciprofloxacin 20.75% 105 4 2.39 16.24% 208 5 1.94 
ns 
(0.91) 
R03BB04 Tiotropium bromide 19.34% 342 5 8.34 13.51% 605 7 6.80 
ns 
(0.82) 
J01DC02 Cefuroxime 17.92% 117 6 3.08 27.01% 329 2 1.85 
ns 
(0.67) 
J01CR22 Amoxicillin/Clavulanic 
acid 16.51% 92 7 2.63 8.80% 103 13 1.78 
ns 
(0.45) 
J01FA10 Azithromycin 15.57% 87 8 2.64 8.65% 117 14 2.05 0.004 
R03AK06 Salmeterol/ Fluticason 14.62% 257 9 8.29 13.20% 599 9 6.89 
ns 
(0.66) 
R03BA02 Budesonide 14.15% 176 10 5.87 10.62% 355 10 5.07 
ns 
(0.85) 
J01FA09 Clarithromycin 12.74% 57 11 2.11 6.37% 117 16 2.79 
ns  
(0.05)    
J01AA02 Doxycyclin 12.26% 52 12 2.00 13.35% 179 8 2.03 
ns 
(0.73) 
R03AC13 Formoterol 11.32% 181 13 7.54 14.57% 646 6 6.73 
ns 
(0.47) 
R01AD09 Mometason 10.85% 112 14 4.87 5.31% 120 19 3.43 
ns      
(0.41) 
R05CB01 Acetylcysteine 10.38% 133 15 6.05 4.86% 120 21 3.75 
ns 
(0.45) 
R03AK03 Ipatropium 
bromide/Fenoterol  9.91% 141 16 6.71 5.92% 316 18 8.10 
ns 
(0.89) 
J01MA12 Levofloxacin 9.43% 91 17 4.55 9.41% 120 12 1.94 
ns 
(0.57) 
J01MA14 Moxifloxacin 8.96% 43 18 2.26 6.07% 78 17 1.95 
ns 
(0.64) 
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J01FF01 Clindamycin 8.02% 32 19 1.88 10.32% 139 11 2.04 
ns 
(0.89) 
J01FA06 Roxithromycin 8.02% 24 19 1.41 8.19% 113 15 2.09 
ns 
(1.0) 
R03DA04 Theophyllin 6.60% 96 21 6.86 4.10% 278 24 10.30 
ns       
(0.60) 
J01CE02 Phenoxymethylpenicillin 6.60% 28 21 2.00 5.16% 63 20 1.85 
ns 
(0.23) 
J01EE01 Sulfamethoxazol/ 
Trimethoprim 6.60% 38 21 2.71 4.25% 64 23 2.29 
ns 
(0.09) 
R03BB05 Aclidinium  6.13% 48 24 3.69 1.82% 65 26 5.42 0.002 
R03BB01 Ipratropium bromide 6.13% 72 24 5.54 2.28% 70 25 4.67 
ns 
(0.83) 
              
 
*Chi-square testing
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Table 6. Unadjusted mortality rates by follow-up years 
  
Group Time Patients at risk Patients diseased Mortality 
Control  Year 1 685 26 3.80% 
Year 2 659 27 4.10% 
 Year 3 632 19 3.01% 
 Total 685 72 10.51% 
Bronchiectasis Year 1 231 19 8.23% 
 Year 2 212 25 11.79 
 Year 3 187 17 9.09% 
 Total 231 61 26.41% 
Bronchiectasis 
w/o 
COPD 
Year 1 103 0 0.0% 
Year 2 103 6 5.83% 
Year 3 97 9 9.28% 
Total 103 15 14.56% 
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